PMID- 26051219
OWN - NLM
STAT- MEDLINE
DCOM- 20160706
LR  - 20220408
IS  - 1528-8447 (Electronic)
IS  - 1526-5900 (Linking)
VI  - 16
IP  - 10
DP  - 2015 Oct
TI  - A Systematic Review of Prospective Studies Reporting Adverse Events of Commonly 
      Used Opioids for Cancer-Related Pain: A Call for the Use of Standardized Outcome 
      Measures.
PG  - 935-46
LID - S1526-5900(15)00683-5 [pii]
LID - 10.1016/j.jpain.2015.05.006 [doi]
AB  - Data on the tolerability of opioids in patients with cancer-related pain are 
      limited. Here, we report a systematic review that includes all published 
      prospective studies reporting adverse events (AEs) of morphine, oxycodone, 
      fentanyl, methadone, or hydromorphone for cancer-related pain in patients naive 
      for these opioids. We included 25 studies describing 31 treatment cohorts, made 
      an overview of study characteristics, and reported rates of AEs per type of 
      opioid. The frequency of the most commonly reported AEs varied widely: nausea 
      from 3 to 85%, vomiting from 4 to 50%, constipation from 5 to 97%, drowsiness 
      from 3 to 88%, and dry mouth from 1 to 94%. There was a large heterogeneity among 
      included studies, especially regarding the assessment and reporting of AEs. We 
      describe how differences in assessment and reporting influence outcome rates. 
      Although AEs are an important issue in daily clinical practice, realistic 
      incidence rates of AEs per type of opioid are unknown because of the immense 
      heterogeneity among studies. PERSPECTIVE: Although opioid-related adverse events 
      are an important issue when treating cancer-related pain, realistic rates of 
      adverse events per type of opioid are unknown because of immense heterogeneity 
      among studies and lack of systematic assessment and reporting. There is an urgent 
      need for studies with standardized outcome measures and reporting.
CI  - Copyright (c) 2015 American Pain Society. Published by Elsevier Inc. All rights 
      reserved.
FAU - Oosten, Astrid W
AU  - Oosten AW
AD  - Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The 
      Netherlands. Electronic address: a.oosten@erasmusmc.nl.
FAU - Oldenmenger, Wendy H
AU  - Oldenmenger WH
AD  - Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The 
      Netherlands.
FAU - Mathijssen, Ron H J
AU  - Mathijssen RH
AD  - Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The 
      Netherlands.
FAU - van der Rijt, Carin C D
AU  - van der Rijt CC
AD  - Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The 
      Netherlands; Netherlands Comprehensive Cancer Organisation, Utrecht, The 
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20150605
PL  - United States
TA  - J Pain
JT  - The journal of pain
JID - 100898657
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Analgesics, Opioid/*adverse effects
MH  - Drug-Related Side Effects and Adverse Reactions/diagnosis/etiology
MH  - Humans
MH  - Neoplasms/*complications
MH  - Outcome Assessment, Health Care/*methods/standards
MH  - Pain/*drug therapy/*etiology
MH  - Prospective Studies
OTO - NOTNLM
OT  - Opioids
OT  - adverse events
OT  - cancer
OT  - pain
OT  - side effects
EDAT- 2015/06/09 06:00
MHDA- 2016/07/07 06:00
CRDT- 2015/06/09 06:00
PHST- 2015/01/31 00:00 [received]
PHST- 2015/04/30 00:00 [revised]
PHST- 2015/05/19 00:00 [accepted]
PHST- 2015/06/09 06:00 [entrez]
PHST- 2015/06/09 06:00 [pubmed]
PHST- 2016/07/07 06:00 [medline]
AID - S1526-5900(15)00683-5 [pii]
AID - 10.1016/j.jpain.2015.05.006 [doi]
PST - ppublish
SO  - J Pain. 2015 Oct;16(10):935-46. doi: 10.1016/j.jpain.2015.05.006. Epub 2015 Jun 
      5.